Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage

被引:117
作者
Bachmann, Rosilla F. [1 ]
Wang, Yun [1 ]
Yuan, Peixiong [1 ]
Zhou, Rulun [1 ]
Li, Xiaoxia [1 ]
Alesci, Salvatore [1 ]
Du, Jing [1 ]
Manji, Husseini K. [1 ]
机构
[1] NIMH, NIH, Mol Pathophysiol Lab, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA
关键词
Bcl-2; lithium; methamphetamine; mitochondria; valproate; INCREASES BCL-2 EXPRESSION; MOOD-STABILIZING AGENTS; CNS IN-VIVO; BIPOLAR DISORDER; OXIDATIVE-PHOSPHORYLATION; CYTOCHROME-C; PERMEABILITY TRANSITION; OXYGEN-CONSUMPTION; PREFRONTAL CORTEX; INDUCED APOPTOSIS;
D O I
10.1017/S1461145708009802
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Accumulating evidence suggests that mitochondrial dysfunction plays a critical role in the progression of a variety of neurodegenerative and psychiatric disorders. Thus, enhancing mitochondrial function could potentially help ameliorate the impairments of neural plasticity and cellular resilience associated with a variety of neuropsychiatric disorders. A series of studies was undertaken to investigate the effects of mood stabilizers on mitochondrial function, and against mitochondrialty mediated neurotoxicity. We found that long-term treatment with lithium and valproate (VPA) enhanced cell respiration rate. Furthermore, chronic treatment with lithium or VPA enhanced mitochondrial function as determined by mitochondrial membrane potential, and mitochondrial oxidation in SH-SY5Y cells. In-vivo studies showed that long-term treatment with lithium or VPA protected against methamphetamine (Meth)-induced toxicity at the mitochondrial level. Furthermore, these agents prevented the Meth-induced reduction of mitochondrial cytochrome c, the mitochondrial anti-apoptotic Bcl-2/Bax ratio, and mitochondrial cytochrome oxidase (COX) activity. Oligoarray analysis demonstrated that the gene expression of several proteins related to the apoptotic pathway and mitochondrial functions were altered by Meth, and these changes were attenuated by treatment with lithium or VPA. One of the genes, Bcl-2, is a common target for lithium and VPA. Knock-down of Bcl-2 with specific Bcl-2 siRNA reduced the lithium- and VPA-induced increases ill mitochondrial oxidation. These findings illustrate that lithium and VPA enhance mitochondrial function and protect against mitochondrially mediated toxicity. These agents may have potential clinical utility in the treatment of other diseases associated with impaired mitochondrial function, such as neurodegenerative diseases and schizophrenia.
引用
收藏
页码:805 / 822
页数:18
相关论文
共 66 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   Brain network dysfunction in bipolar disorder [J].
Adler, CM ;
DelBello, MP ;
Strakowski, SM .
CNS SPECTRUMS, 2006, 11 (04) :312-320
[3]   A rapid method for the isolation of metabolically active mitochondria from rat neurons and astrocytes in primary culture [J].
Almeida, A ;
Medina, JM .
BRAIN RESEARCH PROTOCOLS, 1998, 2 (03) :209-214
[4]   Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine [J].
Bar-Am, O ;
Weinreb, O ;
Amit, T ;
Youdim, MBH .
FASEB JOURNAL, 2005, 19 (11) :1899-+
[5]  
Belloc F, 2000, CYTOMETRY, V40, P151, DOI 10.1002/(SICI)1097-0320(20000601)40:2<151::AID-CYTO9>3.0.CO
[6]  
2-9
[7]   MIBG inhibits respiration: Potential for radio- and hyperthermic sensitization [J].
Biaglow, JE ;
Manevich, Y ;
Leeper, D ;
Chance, B ;
Dewhirst, MW ;
Jenkins, WT ;
Tuttle, SW ;
Wroblewski, K ;
Glickson, JD ;
Stevens, C ;
Evans, SM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (04) :871-876
[8]  
Bowden CL, 1996, AM J PSYCHIAT, V153, P765
[9]   Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite [J].
Brown, JM ;
Quinton, MS ;
Yamamoto, BK .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (02) :429-436
[10]   The energetics of Huntington's disease [J].
Browne, SE ;
Beal, MF .
NEUROCHEMICAL RESEARCH, 2004, 29 (03) :531-546